Back to search results

Evaluating a Family History Screening Program for BRCA-Associated Cancers

This study is testing an improved family history screening program to help more women in rural Georgia understand their risk for breast and ovarian cancers linked to BRCA gene changes. The program, called the Adapted Family History Screening Program, uses community outreach to raise awareness and make it easier to get screened. Researchers want to see if this new approach helps more women get screened and if the results are understood correctly. You may be able to join if you are a woman aged 25 or older who receives care in public health clinics in Southwest Georgia. The study aims to enroll about 3209 participants.

Study design
This is an interventional study that will compare the Adapted Family History Screening Program to the current screening program in up to 6 public health clinics. It involves about 3209 women.
What's involved
If you are part of the Stakeholder Advisory Committee, you would attend monthly meetings for 14 months, and might participate in interviews or surveys. For other participants, the specific commitments are not detailed.
Compensation
Not stated in the trial record.
Follow-up
The study will measure outcomes like uptake of family history screening and screen result interpretation for up to 6 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06760507

Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

Recruiting
NAAges 25+InterventionalScreening
Emory University
~3,209 participants
Updated 2026-05-26 on ClinicalTrials.gov
What's tested:Adapted Family History Screening Program

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Uptake of family history screening
Measured over Up to 6 years
+1 more outcome measured

Conditions

Breast Cancer
Ovarian Cancer

Explore related trials

Breast CarcinomaMalignant Ovarian Neoplasm

Where it's being run

1 sites across 1 states
Georgia1

Study leadership

  • Yue Guan · PRINCIPAL_INVESTIGATOR · Emory University Hospital/Winship Cancer Institute

Who to contact

Yue Guan, PhD
[email protected]
404-712-1671
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

AIM 1 STAKEHOLDER ADVISORY COMMITTEE: 10 stakeholders representing three constituencies: state cancer control leaders (n=2), participating public health district champions (n=4) (i.e., administrative directors, nurses, clinic staff) and patients (n=4) (i.e., women, age 25 and older who receive their care in the Southwest district)
AIM 1 DISCUSSION FORUM: 25 years or older
AIM 1 DISCUSSION FORUM: Women
AIM 1 DISCUSSION FORUM: English-speaker
AIM 1 DISCUSSION FORUM: Have completed family history screening during the first 3 months of the project at one of 14 public health clinics in Southwest district
AIM 1 ORGANIZATIONAL STAKEHOLDER INTERVIEW: Organizational stakeholders (i.e., medical directors, nurses, and clinic staff) at the 14 clinic sites in Southwest district
AIM 2: Women
AIM 2: Ages 25 and older
AIM 2: Who can read English
AIM 2: Have ever been seen in Women's Health Section through one of participating public health clinics in Southwest district
AIM 3 POST-INTERVENTION INTERVIEW: Participants from aim 2, regardless of whether they completed the recommended genetic services or not (e.g. complete telegenetic session or genetic testing)
AIM 3 WORKSHOP DISCUSSION: Medical and administrative directors, nurses, and clinic staff from the six participating clinic sites

What this trial measures

  • Uptake of family history screeningUp to 6 years

    Defined as the number and proportion of the women older than 25 years served by the clinics who complete screening tool. Screening uptake rate at each site will be calculated with a 95% confidence interval. Comparison between arms will be carried out using a mixed-effects logistic regression model.

  • Screen result interpretationUp to 6 years

    Will be evaluated by recall of screen result calculated as the concordance of participants' self-reported screen result and their actual result (correct/incorrect) and understanding of the likelihood of carrying a BRCA1/2 mutation (correct/incorrect).